Gerri Henwood has served as our President and Chief Executive Officer and a director of the Company since 2019. Ms. Henwood previously served as the President and Chief Executive Officer of Societal CDMO, Inc. (f/k/a Recro Pharma, Inc.), which she founded in 2008, until 2020. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director—Marketing in the International Pharmaceutical Division.

Ms. Henwood previously served on the board of directors of Societal CDMO from 2008 until January 2022, and Tetraphase Pharmaceuticals, Inc., a position she held from May 2015 until the first half of 2020. Ms. Henwood also served on the compensation committee of Tetraphase Pharmaceuticals, Inc. She served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceutical company, from 2004 until its acquisition by Allergan, Inc. in March 2013.

Ms. Henwood holds a B.S. in Biology from Neumann University.

Yong Chan Kim has been a director and Chief Scientific Officer of the Company since July 2023.  Dr. Kim has served as the CEO and Director of TeraImmune, Inc. since April 2019.  Dr. Kim served as Vice President of Research of TeraImmune, LLC from April 2017 until March 2019.  He also previously served as Research Assistant Professor at the Uniformed Services University of the Health Sciences from May 2015 until March 2018.  Dr. Kim received his Ph.D. in Biochemistry from Chungnam National University and completed his post-doctoral fellowship at the Uniformed Services University of the Health Sciences.

Randy Mack currently is a principal in Birch Partners Consulting where he provides input on drug development strategy, clinical trial design/analyses, regulatory agency interactions and business development opportunities.  Prior to his current role, he served as the Senior Vice President, Development at Baudax Bio where he led the development of the company’s pain management and anesthesia drug products. From 2008 to 2014, Randy served as Executive Vice President, Development for MCG, a pharmaceutical incubator and consulting firm.  During this time, Randy provided services on the development of products in oncology, pain management, neurology, infectious disease and urology. From 2005 to 2008, Randy served as Vice President, Project Management and Operations at Adolor Corporation where he oversaw the development programs in the areas of opioid-induced bowel dysfunction and pain management. For more than 15 years, he also held positions of increasing responsibilities at Auxilium, Abbott Laboratories and Harris Laboratories. In these positions he was responsible for the conduct of over 500 clinical trials and the filing of 33 INDs and 6 NDAs. During his career he has authored more than 100 scientific articles, book chapters, abstracts and poster presentations in the areas of gastroenterology, urology, neuroscience, pain management and psychiatric disorders. Mr. Mack holds a B.S. in Biology and Chemistry from the University of Nebraska-Lincoln.

Dr. Stewart McCallum is a board-certified surgeon with extensive expertise across the entire spectrum of pharmaceutical development from the viewpoints of a sponsor and a primary investigator. His pharmaceutical experience spans from target validation to Phase IV, clinical trial development, regulatory reviews, product launches, and fulfilling post-marketing commitments. Dr. McCallum was Chief Medical Officer at Recro Pharma, then Baudax Bio, participating in the approval and launch of Anjeso (IV Meloxicam), a 24-hour intravenous analgesic designed to alleviate moderate to severe pain. Before Baudax Bio, Dr. McCallum held roles of increasing responsibility at GlaxoSmithKline for nine years. Here, he spearheaded clinical development initiatives for novel chemical entities (NCEs) across various medical conditions, including orphan indications. His tenure also encompassed roles such as Clinical Director for the Oncology Business Development Unit and Director of Clinical Pharmacology for the Cardiovascular and Urology Center of Excellence for Drug Development. Before venturing into the pharmaceutical realm, Dr. McCallum was an Assistant Professor of Urology at Stanford University. His academic journey included a Clinical Fellowship at the Department of Urology at New York Hospital – Cornell Medical Center after completing a Residency at the Department of Urology at the University of Toronto. He completed a Comprehensive Surgical Internship at Mount Sinai Hospital in Toronto. Dr. McCallum holds a Doctor of Medicine (MD) from the University of Toronto and a Bachelor of Science (BSc) in Biochemistry, earned with honors, from the University of Western Ontario. His enduring commitment to advancing healthcare and pharmaceutical innovation remains a testament to his career.

Diane Myers serves as Senior Consultant, Regulatory and Quality. Before her role at Baudax Bio, she served as the Senior Vice President, Regulatory and Quality at Recro Pharma from 2008 to November 2019. From 2008 to 2014, Ms. Myers also served as Senior Vice President of Regulatory Affairs and Quality Assurance for MCG, a pharmaceutical incubator and consulting firm. From 2000 to 2008, Ms. Myers served as Vice President of Regulatory Affairs and Quality at Auxilium. In addition, for more than 15 years she held positions of increasing responsibility at GlaxoSmithKline plc in the Quality Control and Quality Assurance groups within the Biopharmaceutical Research and Development Division.

Ms. Myers holds a B.S. in Biology from Neumann University.

Ms. McAndrew, age 49, is a Director with Danforth, an advisory firm focused on providing financial strategy to life science organizations, and has been employed with Danforth since August 2021. Prior to Danforth, Ms. McAndrew was the VP, Corporate Controller of Tmunity Therapeutics, Inc., a biotechnology company, from January 2021 to July 2021. Ms. McAndrew previously served as Head of Accounting Operations at Spark Therapeutics, Inc., a biotechnology company, from March 2015 until January 2021. Prior to this, Ms. McAndrew served as Corporate Controller for over 8 years in other privately held and public companies at various life cycle stages, managing finance, accounting, and other corporate operational functions. Ms. McAndrew is a certified public accountant and holds a B.S. degree in Accounting from King’s College.